Kalaris Therapeutics, Inc. (KLRS) › Capital ExpendituresKalaris Therapeutics, Inc. (KLRS) — Capital ExpendituresAnnual figures by period end, from SEC filings.2019-12-31: $339.0K2020-12-31: $235.0K2021-12-31: $26.0K2025-12-31: $200.0K$200.0K2019-12-31Capital Expenditures (USD)2025-12-31Period endedCapital ExpendituresChange YoYSource filing2025-12-31$200.0K—2026-03-17From 2025-01-012021-12-31$26.0K-88.9%2023-02-15From 2021-01-012020-12-31$235.0K-30.7%2022-02-10From 2020-01-012019-12-31$339.0K—2021-02-12From 2019-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)